Clinical trial · Observational
Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis
Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate. One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis. The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti NMDA Receptor Encephalitis | — | UNRESOLVED | — |
| Autoimmune Encephalitis | — | UNRESOLVED | — |
| Herpetic Encephalitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Description and analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort NMDARE-HSE
- description
- Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
- interventionNames
- Other: Description and analysis
Primary outcomes (1)
- measure
- Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution.
- timeFrame
- at 6 and 12 months
- description
- Retrospective collection of clinical, diagnostic and therapeutic data, evolution at 6 and 12 months.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF * After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF * Without age limit Exclusion Criteria- No respect of inclusion criteria
References
Publications (0)
Data not yet available